IP Library › Granted Patent US 12,195,555
Granted Patent B2
US 12,195,555 · App. 18/469,947 · Granted Jan 14, 2025

Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering

Inventors: Nicolas Gourdin (Marseilles, FR); Laurent Gauthier (Marseilles, FR); Alexandre Tang (Paris, FR); Marielle Chiron (Paris, FR); Angela Virone-Oddos (Paris, FR); Alessandro Masiero (Paris, FR); Jochen Beninga (Frankfurt am Main, DE); Ingo Focken (Frankfurt am Main, DE); Sambasiva Rao (Cambridge, MA); Yanfeng Zhou (Cambridge, MA); Leila Sevigny (Cambridge, MA)
C07K16/468A61P35/00C12N15/63C07K2317/14C07K2317/31C07K2317/41C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,555
App. No.
18/469,947
Granted
Jan 14, 2025
Kind
B2
Abstract

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

Claims (181)

1. A binding protein comprising a first antigen binding domain (ABD) with binding specificity to BCMA and a second ABD with binding specificity to NKp46, wherein:

(a) the first ABD comprises:

(a1) a first immunoglobulin heavy chain variable domain (VH1) comprising:

(i) an HCDR1 comprising the amino acid sequence GFTFSNFGMH (SEQ ID NO: 1),

(ii) an HCDR2 comprising the amino acid sequence VIWSDETNR (SEQ ID NO: 2), and

(iii) an HCDR3 comprising the amino acid DQQYCSSDSCFTWFDP (SEQ ID NO: 3); and

(a2) a first immunoglobulin light chain variable domain (VL1) comprising:

(i) an LCDR1 comprising the amino acid sequence CASSTGTVTPSNYAN (SEQ ID NO: 7),

(ii) an LCDR2 comprising the amino acid sequence DNNSRPP (SEQ ID NO: 8), and

(iii) an LCDR3 comprising the amino acid sequence ALWFGNQWV (SEQ ID NO: 9); and

(b) the second ABD comprises:

(b1) a second immunoglobulin heavy chain variable domain (VH2) comprising:

(i) an HCDR1 comprising the amino acid sequence DYVIN (SEQ ID NO: 80),

(ii) an HCDR2 comprising the amino acid sequence EIYPGSGTNYYNEKFKA (SEQ ID NO: 81), and

(iii) an HCDR3 comprising the amino acid sequence RGRYGLYAMDY (SEQ ID NO: 21); and

(b2) a second immunoglobulin light chain variable domain (VL2) comprising:

(i) an LCDR1 comprising the amino acid sequence RASQDISNYLN (SEQ ID NO: 34),

(ii) an LCDR2 comprising the amino acid sequence YTSRLHS (SEQ ID NO: 35), and

(iii) an LCDR3 comprising the amino acid sequence QQGNTRPWT (SEQ ID NO: 36; or

(b3) a second immunoglobulin VH2 comprising:

(i) an HCDR1 comprising the amino acid sequence GYTFSDYVIN (SEQ ID NO: 19),

(ii) an HCDR2 comprising the amino acid sequence EIYPGSGTN (SEQ ID NO: 20), and

(iii) an HCDR3 comprising the amino acid sequence RGRYGLYAMDY (SEQ ID NO: 21); and

(b4) a second immunoglobulin VL2 comprising:

(i) an LCDR1 comprising the amino acid sequence RASQDISNYLN (SEQ ID NO: 34),

(ii) an LCDR2 comprising the amino acid sequence YTSRLHS (SEQ ID NO: 35), and

(iii) an LCDR3 comprising the amino acid sequence QQGNTRPWT (SEQ ID NO: 36); or

(b5) a second immunoglobulin VH2 comprising:

(i) an HCDR1 comprising the amino acid sequence SDYAWN (SEQ ID NO: 22),

(ii) an HCDR2 comprising the amino acid sequence YITYSGSTSYNPSLES (SEQ ID NO: 23), and

(iii) an HCDR3 comprising the amino acid sequence GGYYGSSWGVFAY (SEQ ID NO: 24); and

(b6) a second immunoglobulin VL2 comprising:

(i) an LCDR1 comprising the amino acid sequence RVSENIYSYLA (SEQ ID NO: 37),

(ii) an LCDR2 comprising the amino acid sequence NAKTLAE (SEQ ID NO: 38), and

(iii) an LCDR3 comprising the amino acid sequence QHHYGTPWT (SEQ ID NO: 39); or

(b7) a second immunoglobulin VH2 comprising:

(i) an HCDR1 comprising the amino acid sequence EYTMH (SEQ ID NO: 25),

(ii) an HCDR2 comprising the amino acid sequence GISPNIGGTSYNQKFKG (SEQ ID NO: 26), and

(iii) an HCDR3 comprising the amino acid sequence RGGSFDY (SEQ ID NO: 27); and

(b8) a second immunoglobulin VL2 comprising:

(i) an LCDR1 comprising the amino acid sequence RASQSISDYLH (SEQ ID NO: 40),

(ii) an LCDR2 comprising the amino acid sequence YASQSIS (SEQ ID NO: 41), and

(iii) an LCDR3 comprising the amino acid sequence QNGHSFPLT (SEQ ID NO: 42); or

(b9) a second immunoglobulin VH2 comprising:

(i) an HCDR1 comprising the amino acid sequence SFTMH (SEQ ID NO: 28),

(ii) an HCDR2 comprising the amino acid sequence YINPSSGYTEYNQKFKD (SEQ ID NO: 29), and

(iii) an HCDR3 comprising the amino acid sequence GSSRGFDY (SEQ ID NO: 30); and

(b10) a second immunoglobulin VL2 comprising:

(i) an LCDR1 comprising the amino acid sequence RASENIYSNLA (SEQ ID NO: 43),

(ii) an LCDR2 comprising the amino acid sequence AATNLAD (SEQ ID NO: 44), and

(iii) an LCDR3 comprising the amino acid sequence QHFWGTPRT (SEQ ID NO: 45); or

(b11) a second immunoglobulin VH2 comprising:

(i) an HCDR1 comprising the amino acid sequence SDYAWN (SEQ ID NO: 31),

(ii) an HCDR2 comprising the amino acid sequence YITYSGSTNYNPSLKS (SEQ ID NO: 32), and

(iii) an HCDR3 comprising the amino acid sequence CWDYALYAMDC (SEQ ID NO: 33); and

(b12) a second immunoglobulin VL2 comprising:

(i) an LCDR1 comprising the amino acid sequence RTSENIYSYLA (SEQ ID NO: 46),

(ii) an LCDR2 comprising the amino acid sequence NAKTLAE (SEQ ID NO: 47), and

(iii) an LCDR3 comprising the amino acid sequence QHHYDTPLT (SEQ ID NO: 48).

2. The binding protein of claim 1 , wherein

the VH1 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 49, and wherein the VL1 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 55.

3. The binding protein of claim 1 , wherein:

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 56, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 64;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 57, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 65;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 58, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 66;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 59, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 67;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 60, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 68;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 61, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 69;

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 62, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 70; or

the VH2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 63, and wherein the VL2 comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 71.

4. The binding protein of claim 1 , further comprising all or part of an immunoglobulin Fc domain or variant thereof.

5. The binding protein of claim 4 , wherein the Fc domain or variant thereof comprises a first Fc heavy chain and a second Fc heavy chain.

6. The binding protein of claim 5 , wherein at least one Fc heavy chain comprises an engineered intrachain disulfide bond mediated by a pair of cysteines (C) that substitute for:

(i) a leucine (L) at amino acid position 242 and a lysine (K) at amino acid position 334;

or

(iii) an arginine (R) at amino acid position 292 and a valine (V) at amino acid position 302;

wherein the amino acid positions are according to EU numbering.

7. The binding protein of claim 6 , wherein the first and the second Fc heavy chain each comprise both the L242C and K334C substitutions.

8. The binding protein of claim 6 , wherein the first and the second Fc heavy chain each comprise both the R292C and V302C substitutions.

9. The binding protein of claim 6 , wherein at least one Fc heavy chain comprises a substitution at amino acid position 332, according to EU numbering.

10. The binding protein of claim 6 , wherein at least one Fc heavy chain further comprises an aspartic acid (D) at amino acid position 239, and a glutamic acid (E) at amino acid position 332, according to EU numbering.

11. The binding protein of claim 1 , comprising at least two polypeptide chains that form at least two antigen binding domains, wherein at least one polypeptide chain comprises a structure represented by the formula:

VL1-L1-VL2-L2-CL  [I];

and at least one polypeptide chain comprises a structure represented by the formula:

VH2-L3-VH1-L4-CH1  [II];

wherein:

CL is an immunoglobulin light chain constant domain;

CH1 is an immunoglobulin CH1 heavy chain constant domain; and

L1, L2, L3, and L4 are amino acid linkers, wherein any one or more of L1, L2, L3, and L4 are optionally absent, and

wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

12. The binding protein of claim 11 , wherein:

L1, L2, L3, and L4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO: 78), GGGGSGGGGSGGGGS (SEQ ID NO: 82), S, RT, TKGPS (SEQ ID NO: 83), GQPKAAP (SEQ ID NO: 84), and GGSGSSGSGG (SEQ ID NO: 85).

13. The binding protein of claim 1 , comprising:

(i) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 72;

(ii) a second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 73; and

(iii) a third polypeptide chain comprising an amino acid sequence of SEQ ID NO: 74.

14. A binding protein comprising a first antigen binding domain (ABD) with binding specificity to BCMA and a second ABD with binding specificity to NKp46, wherein:

(a) the first ABD comprises

(a1) a first immunoglobulin heavy chain variable domain (VH1) comprising:

(i) an HCDR1 sequence from SEQ ID NO: 49, according to Kabat numbering,

(ii) an HCDR2 sequence from SEQ ID NO: 49, according to Kabat numbering, and

(iii) an HCDR3 sequence from SEQ ID NO: 49, according to Kabat numbering, and

(a2) a first immunoglobulin light chain variable domain (VL1) comprising:

(i) an LCDR1 sequence from SEQ ID NO: 55, according to Kabat numbering,

(ii) an LCDR2 sequence from SEQ ID NO: 55, according to Kabat numbering, and

(iii) an LCDR3 sequence from SEQ ID NO: 55, according to Kabat numbering, and

(b) the second ABD comprises

(b1) a second immunoglobulin heavy chain variable domain (VH2) comprising:

(i) an HCDR1 sequence from SEQ ID NO: 56, according to Kabat numbering,

(ii) an HCDR2 sequence from SEQ ID NO: 56, according to Kabat numbering, and

(iii) an HCDR3 sequence from SEQ ID NO: 56, according to Kabat numbering, and

(b2) a second immunoglobulin light chain variable domain (VL2) comprising:

(i) an LCDR1 sequence from SEQ ID NO: 64, according to Kabat numbering,

(ii) an LCDR2 sequence from SEQ ID NO: 64, according to Kabat numbering, and

(iii) an LCDR3 sequence from SEQ ID NO: 64, according to Kabat numbering.

15. The binding protein of claim 14 , comprising:

(i) a first polypeptide chain comprising an amino acid sequence of SEQ ID NO: 72;

(ii) a second polypeptide chain comprising an amino acid sequence of SEQ ID NO: 73; and

(iii) a third polypeptide chain comprising an amino acid sequence of SEQ ID NO: 74.

16. A binding protein comprising a first antigen binding domain (ABD) with binding specificity to BCMA and a second ABD with binding specificity to NKp46, wherein the binding protein comprises:

(i) a first polypeptide chain consisting of an amino acid sequence of SEQ ID NO: 72;

(ii) a second polypeptide chain consisting of an amino acid sequence of SEQ ID NO: 73; and

(iii) a third polypeptide chain consisting of an amino acid sequence of SEQ ID NO: 74.

17. A pharmaceutical composition comprising the binding protein according to claim 1 .

18. The binding protein of claim 4 , wherein all or part of the immunoglobulin Fc domain or variant thereof binds to a human Fc-γ receptor.

19. The binding protein of claim 4 , wherein all or part of the immunoglobulin Fc domain or variant thereof binds to a human CD16A (FcγRIII) polypeptide.

20. The binding protein of claim 4 , wherein the Fc domain comprises a native glycan at amino acid position 297, according to EU numbering.

21. The binding protein of claim 4 , wherein the binding protein is N-glycosylated.

22. The binding protein of claim 9 , wherein the substitution at amino acid position 332 is a glutamic acid (E).

23. The binding protein of claim 9 , wherein at least one Fc heavy chain comprises one or more substitutions at amino acid positions 236, 239, or 330, according to EU numbering.

24. The binding protein of claim 23 , wherein the substitution at amino acid position 236 is an alanine (A), the substitution at amino acid position 239 is an aspartic acid (D), and the substitution at amino acid position 330 is a leucine (L).

25. The binding protein of claim 6 , wherein at least one Fc heavy chain further comprises an alanine (A) at amino acid position 236, an aspartic acid (D) at amino acid position 239, and a glutamic acid (E) at amino acid position 332, according to EU numbering.

26. The binding protein of claim 6 , wherein at least one Fc heavy chain further comprises an alanine (A) at amino acid position 236, an aspartic acid (D) at amino acid position 239, a leucine (L) at amino acid position 330, and a glutamic acid (E) at amino acid position 332, according to EU numbering.

27. The binding protein of claim 1 , wherein (b) the second ABD comprises:

(b1) a second immunoglobulin heavy chain variable domain (VH2) comprising:

(i) an HCDR1 comprising the amino acid sequence DYVIN (SEQ ID NO: 80),

(ii) an HCDR2 comprising the amino acid sequence EIYPGSGTNYYNEKFKA (SEQ ID NO: 81), and

(iii) an HCDR3 comprising the amino acid sequence RGRYGLYAMDY (SEQ ID NO: 21); and

(b2) a second immunoglobulin light chain variable domain (VL2) comprising:

(i) an LCDR1 comprising the amino acid sequence RASQDISNYLN (SEQ ID NO: 34),

(ii) an LCDR2 comprising the amino acid sequence YTSRLHS (SEQ ID NO: 35), and

(iii) an LCDR3 comprising the amino acid sequence QQGNTRPWT (SEQ ID NO: 36).

28. The binding protein of claim 11 , wherein the binding protein comprises three polypeptide chains that form two antigen binding domains, wherein one polypeptide chain comprises a structure represented by the formula:

VL1-L1-VL2-L2-CL  [I];

one polypeptide chain comprises a structure represented by the formula:

VH2-L3-VH1-L4-CH1-hinge-CH2-CH3  [III]; and

one polypeptide chain comprises a structure represented by the formula:

hinge-CH2-CH3  [IV]

wherein:

CL is an immunoglobulin light chain constant domain;

CH1 is an immunoglobulin CHI heavy chain constant domain;

CH2 is an immunoglobulin CH2 heavy chain constant domain;

CH3 is an immunoglobulin CH3 heavy chain constant domain;

hinge is an immunoglobulin hinge region connecting the CH1 and CH2 domains; and

L1, L2, L3, and L4 are amino acid linkers, wherein any one or more of L1, L2, L3, and L4 are optionally absent, and

wherein the polypeptides of formula I and the polypeptides of formula [III] form a cross-over light chain-heavy chain pair.

29. The binding protein of claim 28 , wherein L1, L2, L3, and L4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO: 78), GGGGSGGGGSGGGGS (SEQ ID NO: 82), S, RT, TKGPS (SEQ ID NO: 83), GQPKAAP (SEQ ID NO: 84), and GGSGSSGSGG (SEQ ID NO: 85.

30. The binding protein of claim 1 , wherein the VH1 comprises SEQ ID NO: 49, and wherein the VL1 comprises SEQ ID NO: 55.

31. The binding protein of claim 1 , wherein the VH2 comprises SEQ ID NO: 56, and wherein the VL2 comprises SEQ ID NO: 64.

32. The binding protein of claim 1 , wherein:

(a) the first ABD comprises the VH1 of SEQ ID NO: 49 and the VL1 of SEQ ID NO: 55; and

(b) the second ABD comprises the VH2 of SEQ ID NO: 56 and the VL2 of SEQ ID NO: 64.

33. A binding protein comprising a first antigen binding domain (ABD) with binding specificity to BCMA and a second ABD with binding specificity to NKp46, wherein:

(a) the first ABD comprises

(a1) a first immunoglobulin heavy chain variable domain (VH1) comprising:

(i) an HCDR1 sequence from SEQ ID NO: 49, according to IMGT numbering,

(ii) an HCDR2 sequence from SEQ ID NO: 49, according to IMGT numbering, and

(iii) an HCDR3 sequence from SEQ ID NO: 49, according to IMGT numbering, and

(a2) a first immunoglobulin light chain variable domain (VL1) comprising:

(i) an LCDR1 sequence from SEQ ID NO: 55, according to IMGT numbering,

(ii) an LCDR2 sequence from SEQ ID NO: 55, according to IMGT numbering, and

(iii) an LCDR3 sequence from SEQ ID NO: 55, according to IMGT numbering; and

(b) the second ABD comprises

(b1) a second immunoglobulin heavy chain variable domain (VH2) comprising:

an HCDR1 sequence from SEQ ID NO: 56, according to IMGT numbering,

an HCDR2 sequence from SEQ ID NO: 56, according to IMGT numbering, and

an HCDR3 sequence from SEQ ID NO: 56, according to IMGT numbering, and

(b2) a second immunoglobulin light chain variable domain (VL2) comprising:

an LCDR1 sequence from SEQ ID NO: 64, according to IMGT numbering,

an LCDR2 sequence from SEQ ID NO: 64, according to IMGT numbering, and

an LCDR3 sequence from SEQ ID NO: 64, according to IMGT numbering.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: BENINGA, JOCHEN; FOCKEN, INGO
To: SANOFI
Reel/Frame 069424/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: RAO, SAMBASIVA; SEVIGNY, LEILA; ZHOU, YANFENG
To: SANOFI
Reel/Frame 069425/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: CHIRON, MARIELLE; MASIERO, ALESSANDRO; VIRONE-ODDOS, ANGELA; TANG, ALEXANDRE
To: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Reel/Frame 069425/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
To: SANOFI
Reel/Frame 069425/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: GAUTHIER, LAURENT; GOURDIN, NICOLAS
To: INNATE PHARMA
Reel/Frame 069425/0291 →
Priority Claims (2)
EP 22305783 · May 27, 2022 · regional
EP 22306564 · Oct 14, 2022 · regional
Continuity (6)
Continuation 18202590 · May 26, 2023
Provisional Application 63454158 · Mar 23, 2023
Provisional Application 63487470 · Feb 28, 2023
Provisional Application 63425639 · Nov 15, 2022
Provisional Application 63416081 · Oct 14, 2022
Related Publication 20240034816A1 · Feb 1, 2024
References Cited (201)
US 5288931A · Chang et al. · 1994 [cited by applicant]
US 6177078B1 · Lopez · 2001 [cited by applicant]
US 6733743B2 · Jordan · 2004 [cited by applicant]
US 7112660B1 · Domingues et al. · 2006 [cited by applicant]
US 7220829B2 · Rossjohn et al. · 2007 [cited by applicant]
US 7435549B1 · Kufer et al. · 2008 [cited by applicant]
US 7651678B2 · Jordan · 2010 [cited by applicant]
US 7919089B2 · Kufer et al. · 2011 [cited by applicant]
US 8492119B2 · Tawara et al. · 2013 [cited by applicant]
US 8535669B2 · Vairo et al. · 2013 [cited by applicant]
US 8569461B2 · Panousis · 2013 [cited by applicant]
US 8609149B2 · Callahan et al. · 2013 [cited by applicant]
US 8790645B2 · Kufer et al. · 2014 [cited by applicant]
US 8852551B2 · Jordan · 2014 [cited by applicant]
US 9155802B2 · Pedersen et al. · 2015 [cited by applicant]
US 9217039B2 · Pedersen et al. · 2015 [cited by applicant]
US 9394370B2 · Tawara et al. · 2016 [cited by applicant]
US 9540441B2 · Tawara et al. · 2017 [cited by applicant]
US 9683048B2 · Freeman et al. · 2017 [cited by applicant]
US 9758585B2 · Vairo et al. · 2017 [cited by applicant]
US 9815898B2 · Freeman et al. · 2017 [cited by applicant]
US 9850310B2 · Gaudet et al. · 2017 [cited by applicant]
US 9879087B2 · Desander et al. · 2018 [cited by applicant]
US 9944709B2 · Galetto · 2018 [cited by applicant]
US 10005832B2 · Yoshida et al. · 2018 [cited by applicant]
US 10047161B2 · Panousis · 2018 [cited by applicant]
US 10113003B2 · Gauthier et al. · 2018 [cited by applicant]
US 10155818B2 · Seibert et al. · 2018 [cited by applicant]
US 10179817B2 · Sagert et al. · 2019 [cited by applicant]
US 10221246B2 · Pedersen et al. · 2019 [cited by applicant]
US 10280226B2 · Seibert et al. · 2019 [cited by applicant]
US 10508150B2 · Jordan · 2019 [cited by applicant]
US 10519234B2 · Gauthier et al. · 2019 [cited by applicant]
US 10611814B2 · Bachmann et al. · 2020 [cited by applicant]
US 10709775B2 · Dusseaux · 2020 [cited by applicant]
US 11001629B2 · Gauthier et al. · 2021 [cited by applicant]
US 11208480B2 · Gauthier et al. · 2021 [cited by applicant]
US 11267897B2 · Gauthier et al. · 2022 [cited by applicant]
US 11692039B2 · Chiron et al. · 2023 [cited by applicant]
US 20030004547A1 · Sailer et al. · 2003 [cited by applicant]
US 20100209341A1 · Vairo et al. · 2010 [cited by applicant]
US 20110052574A1 · Dick et al. · 2011 [cited by applicant]
US 20120070448A1 · Tawara et al. · 2012 [cited by applicant]
US 20130230510A1 · Dick et al. · 2013 [cited by applicant]
US 20140086912A1 · Panousis · 2014 [cited by applicant]
US 20140154743A1 · Levy et al. · 2014 [cited by applicant]
US 20140178364A1 · Vairo et al. · 2014 [cited by applicant]
US 20150017180A1 · Vairo et al. · 2015 [cited by applicant]
US 20150132315A1 · Jordan · 2015 [cited by applicant]
US 20150152185A1 · Dick et al. · 2015 [cited by applicant]
US 20150307615A1 · Panousis · 2015 [cited by applicant]
US 20170029515A1 · Dick et al. · 2017 [cited by applicant]
US 20180079818A1 · Dick et al. · 2018 [cited by applicant]
US 20180244786A1 · Lopez et al. · 2018 [cited by applicant]
US 20190055315A1 · Gauthier et al. · 2019 [cited by applicant]
US 20190185573A1 · Wilson et al. · 2019 [cited by applicant]
US 20200031942A1 · Jordan · 2020 [cited by applicant]
US 20200048345A1 · Gauthier et al. · 2020 [cited by applicant]
US 20200131268A1 · Gauthier et al. · 2020 [cited by applicant]
US 20200207861A1 · Dick et al. · 2020 [cited by applicant]
US 20210269523A1 · Gauthier et al. · 2021 [cited by applicant]
US 20210388097A1 · Zhou et al. · 2021 [cited by applicant]
US 20220135676A1 · Gauthier et al. · 2022 [cited by applicant]
US 20220213202A1 · Amara et al. · 2022 [cited by applicant]
US 20230416383A1 · Chiron et al. · 2023 [cited by applicant]
US 20240117062A1 · Beninga et al. · 2024 [cited by applicant]
CN 105367657A · 2016 [cited by applicant]
EP 1161453A1 · 2001 [cited by applicant]
EP 1032660B1 · 2009 [cited by applicant]
EP 1263463B1 · 2011 [cited by applicant]
EP 2536468A1 · 2012 [cited by applicant]
EP 2626069A1 · 2013 [cited by applicant]
EP 2426148B1 · 2015 [cited by applicant]
EP 2778175B1 · 2016 [cited by applicant]
EP 2329847B1 · 2016 [cited by applicant]
EP 2635604B1 · 2016 [cited by applicant]
EP 2536430B1 · 2016 [cited by applicant]
EP 2436397B1 · 2017 [cited by applicant]
EP 2575444B1 · 2017 [cited by applicant]
EP 3189081A1 · 2017 [cited by applicant]
EP 1629013B1 · 2018 [cited by applicant]
EP 3156421B1 · 2018 [cited by applicant]
EP 2635605B1 · 2018 [cited by applicant]
EP 3097121B1 · 2018 [cited by applicant]
EP 3119807B1 · 2019 [cited by applicant]
WO WO1997024373A1 · 1997 [cited by applicant]
WO WO1999025818A1 · 1999 [cited by applicant]
WO WO2000047620A1 · 2000 [cited by applicant]
WO WO2001066139A1 · 2001 [cited by applicant]
WO WO2004106383A1 · 2004 [cited by applicant]
WO WO2006064136A1 · 2006 [cited by applicant]
WO WO2009070844A1 · 2009 [cited by applicant]
WO WO2010094068A1 · 2010 [cited by applicant]
WO WO2010126066A1 · 2010 [cited by applicant]
WO WO2010137654A1 · 2010 [cited by applicant]
WO WO2011100786A1 · 2011 [cited by applicant]
WO WO2012021934A1 · 2012 [cited by applicant]
WO WO2012059857A2 · 2012 [cited by applicant]
WO WO2012059858A1 · 2012 [cited by applicant]
WO WO2012089814A1 · 2012 [cited by applicant]
WO WO2014138805A1 · 2014 [cited by applicant]
WO WO2014138819A1 · 2014 [cited by applicant]
WO WO2015112900A1 · 2015 [cited by applicant]
WO WO2015184099A1 · 2015 [cited by applicant]
WO WO2015193406A1 · 2015 [cited by applicant]
WO WO2015197593A1 · 2015 [cited by applicant]
WO WO2015197598A2 · 2015 [cited by applicant]
WO WO2016030414A1 · 2016 [cited by applicant]
WO WO2016036937A1 · 2016 [cited by applicant]
WO WO2016077526A1 · 2016 [cited by applicant]
WO WO2016116626A1 · 2016 [cited by applicant]
WO WO2016120216A1 · 2016 [cited by applicant]
WO WO2016179257A2 · 2016 [cited by applicant]
WO WO2016201065A1 · 2016 [cited by applicant]
WO WO2016207098A1 · 2016 [cited by applicant]
WO WO2016207273A2 · 2016 [cited by applicant]
WO WO2016207278A1 · 2016 [cited by applicant]
WO WO2017083582A1 · 2017 [cited by applicant]
WO WO2017096179A1 · 2017 [cited by applicant]
WO WO2017096189A1 · 2017 [cited by applicant]
WO WO2017096276A1 · 2017 [cited by applicant]
WO WO2017096281A1 · 2017 [cited by applicant]
WO WO2017114694A1 · 2017 [cited by applicant]
WO WO2017160954A1 · 2017 [cited by applicant]
WO WO2017214433A1 · 2017 [cited by applicant]
WO WO2019101695A1 · 2019 [cited by applicant]
WO WO2019226617A1 · 2019 [cited by applicant]
WO WO2022200525A1 · 2022 [cited by applicant]
WO WO2022212470A2 · 2022 [cited by applicant]
WO WO2022258662A1 · 2022 [cited by applicant]
Mariuzza, R.A. etal. The Structural Basis of Antigen-Antibody Recognition1 Annu. Rev. Biophys. Biphys. Chem. 16:139-159, 1987. [cited by examiner]
MacCallum et al. “Antibody-antigen interactions: contact analysis and binding site topography”, Journal of Molecular Biology, 1996. vol. 262, pp. 732-745. [cited by examiner]
De Pascalis et al. “Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanzied monoclonal antibody”, Jou… [cited by examiner]
Goel et al. Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response. 1 J. Immunol. 173(12)7358-7367, 2004. [cited by examiner]
Kahn et al. ‘Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in Germline Antibodies.’ J. Immunol. 192:5398-5405, 2014. [cited by examiner]
Poosarla et al. ‘Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity.’ Biotech. Bioeng. 114(6): 1331-1342, 2017. [cited by examiner]
Alaoui-Ismaili, “Design of second generation therapeutic recombinant bone morphogenetic proteins”, Cytokine Growth Factor Rev., 2009, 20(5-6): 501-507. [cited by applicant]
Almagro et al., Humanization of Antibodies, Frontiers in Bioscience, Jan. 2008, 13(5): 1619-1633. [cited by applicant]
Bachiller et al., “Natural Killer Cells in Immunotherapy: Are We Nearly There?”, Cancers, 2020, 12(3139): 1-27. [cited by applicant]
Bernier et al., “Pharmacological chaperone action on G-protein-coupled receptors”, Curr. Opin. Pharmacol., 2004, 4: 528-533. [cited by applicant]
Bhattacharya et al., “Impact of genetic variation on three dimensional structure and function of proteins”, PLoS ONE, 2017, 12(3): e0171355. [cited by applicant]
Blanchard et al., “Multi-Specific Antibody Technology Engaging NK Cells in Oncology”, PEGS Europe, 2018. [cited by applicant]
Cai et al, “C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo”, Biotechnol. Bioeng. 2011, 108: 404-412. [cited by applicant]
Demaria , “Harnessing NK Cells in Cancer Therapies by Antibody-Based NK Cell Engager Therapeutics (ANKET)”, PEGS Boston, May 4, 2022. [cited by applicant]
Demaria et al., “Natural killer cell engagers in cancer immunotherapy: Naxt generation of immuno-oncology treatments”, Eur. J. Immunol., 2021, 51(8): 1934-1942. [cited by applicant]
Demaria, “Antitumor immunity induced by antibody-based NK cell engager therapeutics armed with not-alpha IL-2 variant”, Cell Reports Medicine, Oct. 18, 2022, 3: 100783. [cited by applicant]
Dickopf et al., “Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies”, Computational and Structural Biotechnology Journal, May 14, 2020, 18: 1221-1227. [cited by applicant]
Dilillo et al., “A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells”, Bllod Advances, Mar. 9, 2021, 5(5): 1291-1304. [cited by applicant]
Dondelinger et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition”, Frontiers in Immunology, Oct., 16, 2018, 9(2278): 1-15. [cited by applicant]
Ellwanger et al., “Redirected Optimized Cell Killing (Rock®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity”, MABS, Jun. 7, 2019, 11(5): 899-918. [cited by applicant]
Ernst et al., “Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1”, Blood Cancer Journal, Jan. 15, 2019, 9(6): 1-11. [cited by applicant]
Extended European Search Report for European Patent Application No. 20306717.8, mailed Jun. 7, 2021. [cited by applicant]
Extended European Search Report for European Patent Application No. 22305783.7, mailed Nov. 7, 2022. [cited by applicant]
Extended European Search Report for European Patent Application No. 22305784.5, mailed Nov. 7, 2022. [cited by applicant]
Fleming et al., “Trifunctional antibodies unleash NK cells”, Nature Reviews—Immunology, Jul. 2019, 19: 411. [cited by applicant]
Gantke et al., “AFM26—Targeting B Cell Maturation Antigen (BCMA) for NK Cell- Mediated Immunotherapy of Multiple Myeloma”, Blood, 2017, 130(Suppl. 1): 3082. [cited by applicant]
Gauthier et al., “#852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC”, Poster, SITC, Nov. 10-14, 2021. [cited by applicant]
Gauthier et al., “Abstract 852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC”, Journal for Immuno Therapy of Cancer, Nov. 2021, 9(Suppl. 2): A893. [cited by applicant]
Gauthier et al., “Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity”, Cell, Jun. 13, 2019, 177(7): 1701-1713, e16, ePublished May 30, 2019. [cited by applicant]
Gauthier et al., “Multifunctional Natural Killer Cell Engagers”, PEGS Europe Summit, Engineering Biospecific Antibodies, Nov. 4, 2021. [cited by applicant]
Gauthier et al., “Poster #P776 Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity”, SITC, 2019. [cited by applicant]
Guo et al., “Protein tolerance to random amino acid change”, PNAS USA, 2004, 101(25): 9205-9210. [cited by applicant]
Hipp et al., “A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple lyeloma induces lysis in vitro and in vivo”, Leukemia, Jan. 13, 2017, 31(8): 1743-1751, online preview Dec. 27, 2016. [cited by applicant]
Innate Pharma, “Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development”, Press Release, Jan. 5, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2023/64282, mailed Aug. 28, 2023. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2023/64283, mailed Aug. 21, 2023. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2021/062494, mailed Mar. 29, 2022. [cited by applicant]
Jacobsen et al., “Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability”, The Journal of Biological Chemistry, Feb. 3, 2017, 292(5): 1865-1875. [cited by applicant]
Lazar et al, “Engineered antibody Fc variants with enhanced effector function”, PNAS, 2006, vol. 103, No. 11, pp. 4005-4010. [cited by applicant]
Moraga et al., “Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands”, Cell, Mar. 12, 2015, 160(6): 1196-1208, ePublished Feb. 26, 2015. [cited by applicant]
Mullard, “FDA approves second BCMA-targeted CAR-T cell therapy”, Nature Reviews, Drug Discovery, Apr. 2022, 21(4): 249. [cited by applicant]
Panowski et al., “Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma”, Molecular Cancer Therapeutics, Nov. 2019, 18(11): OF1-OF13, Epub. … [cited by applicant]
Shi et al., “A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity”, Journal of Biological Chemistry, Apr. 20, 2018, 293(16): 5909-5919, Published online Feb. 26, 2018. [cited by applicant]
Stein et al., “Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells”, British Journal of Haematology, Mar. 1, 2010, 148(6): 87… [cited by applicant]
Sun et al., “Monoclonal Antibody 7G3 Recognizes the N-Terminal Domain of the Human Interleukin-3 (IL-3) Receptor a-Chain and Functions as a Specific IL-3 Receptor Antagonist”, Blood, Jan. 1, 1996, 87(1): 83-92. [cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability”, Curr. Opin. Struc. Biol., 2009, 19: 596-604. [cited by applicant]
Uchanska-Ziegler et al., “Human Single-Chain Fv Fragments Specific for Natural Killer Cell Receptors from Phage Display Libraries”, Methods in Molecular Biology, Feb. 2000, 121: 219-237. [cited by applicant]
Ulloa-Aguirre et al., “Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease”, Traffic, 2004, 5: 821-837. [cited by applicant]
Vidarsson et al, “lgG subclasses and allotypes: from structure to effector functions”, Frontiers in Immunology, 2014, vol. 5, Article 521, pp. 1-17. [cited by applicant]
Vivier, “Natural Killer Cell Engagers”, FOCIS—Federation of Clinical Immunology Societies, Jun. 6, 2021. [cited by applicant]
Vivier, “Targeting Innate Immunity in Cancer”, AACR, 2019. [cited by applicant]
Wang et al., “IgG Fc engineering to modulate antibody effector functions”, Protein Cell 2018, vol. 9, No., 1, pp. 63-73. [cited by applicant]
Wang et al., “BCMA-targeting Bispecific Antibody That Simultaneously Simulates MKG2D-enhanced Efficacy Against Multiple Myeloma”, Journal of Immunotherapy, Jul./Aug. 2020, 43(6): 175-188. [cited by applicant]
Watkins-Yoon et al., “CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma”, Blood, American Society of Hematology, Nov. 13, 2019, vol. 134, p.… [cited by applicant]
Zhou et al., “The landscape of bispecific T cell engager in cancer treatment”, Biomarker Research, 2021, 9(38): 1-23. [cited by applicant]
U.S. Appl. No. 18/324,668, filed May 26, 2023, Jochen Beninga, Anit-BCMA Antibodies. [cited by applicant]
U.S. Appl. No. 17/566,142 2022/0213202, U.S. Pat. No. 11,692,039, filed Dec. 30, 2021 Jul. 7, 2022 Jul. 4, 2023, Marielle Chiron, Multifunctional Natural Killer (NK) Cell Engagers Binding to NKp46 and CD123. [cited by applicant]
U.S. Appl. No. 18/308,778 2023/0416383, filed Apr. 28, 2023 Dec. 28, 2023, Marielle Chiron, Multifunctional Natural Killer (NK) Cell Engagers Binding to NKp46 and CD123. [cited by applicant]
U.S. Appl. No. 18/202,590, filed May 26, 2023, Nicolas Gourdin, Natural Killer (NK) Cell Engagers Binding to NKp46 and Bcma Variants with FC-Engineering. [cited by applicant]
U.S. Appl. No. 18/469,947 2024/0034816, filed Sep. 19, 2023 Feb. 1, 2024, Nicolas Gourdin, Natural Killer (NK) Cell Engagers Binding to NKp46 and Bcma Variants with FC-Engineering. [cited by applicant]
U.S. Appl. No. 18/324,668 2024/0117062, filed May 26, 2023 Apr. 11, 2024, Jochen Beninga, Anit-BCMA Antibodies. [cited by applicant]
Affimed N.V., “Affimed Announces Presentation of Data on Genentech's RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed's ROCK® Platform, at AACR Virtual Annual Meeting II”, Jun. 22, 2020, Heidelberg,… [cited by applicant]
Draghi et al., “A Novel Class of Innate Cell Engagers targeting NKp30”, Compass Therapeutics, SITC, Nov. 12, 2019. [cited by applicant]
Draghi et al., “Preclinical characterization of NKp30xBCMA, a novel class of NK-Cell Engagers”, Compass Therapeutics, AACR Annual Meeting, Mar. 25, 2019. [cited by applicant]
Draghi, “A Novel Class of NK-Engagers Targeting NKp30”, Compass Therapeutics, Keystone Cancer Immunology Symposium, Mar. 25, 2019, Poster #1010. [cited by applicant]
Ellwanger et al., “Redirected Optimized Cell Killing (Rock®): A novel multispecific antibody platform for innate immune cell engagement to fight cancer”, Oct. 2, 2019, Poster 159. [cited by applicant]
Gantke et al., “AFM26—Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma”, 59th ASH Annual Meeting, Dec. 9-12, 2017, Poster 3082. [cited by applicant]
Kakiuchi-Kiyota et al., “Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma”, Conference Paper: Proceedings: AACR Annual Me… [cited by applicant]
Plesner et al., “A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma”, ASH Annual Meeting, Dec. 9-12, 2021, Hybrid Format, Pos… [cited by applicant]
Sanofi, “Core Study Information and Informed Consent Form for SAR445514-TCD17710, First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK cell engager (NKCE) targeting B-cell ma… [cited by applicant]
Seattle Genetics, Inc., “Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma”, Business Wire, Nov. 14, 2018. [cited by applicant]